Bausch Health announces good Phase III results from psoriasis therapy

Bausch Health–formerly known as Valeant–yesterday reported on a press release that the Journal of Drugs in Dermatology has published results from as many as two Phase III clinical trials, assessing corticosteroid Bryhali (halobetasol propionate) Lotion, 0.01% in patients with psoriasis. The results show that the new Bausch Health’s therapy reaches its primary endpoints: at four weeks post treatment, no rebound of symptoms was observed. The company’s shares positively reacted to good news by rising more than 6%.

(Source: Bausch Health)